Table 3.
Five-year survival rates among testicular cancer patients from different racial groups, stratified by age, marital status, stage at diagnosis, location, and treatment
| Survival rates | Total | NHW | HW | Black | API | P-value |
|---|---|---|---|---|---|---|
| All ages | 94.4 | 95.0 | 92.3 | 88.8 | 91.7 | |
| (94.1–94.6) | (94.7–95.3) | (91.5–93.0) | (86.6–90.6) | (89.9–93.1) | ||
| 0–39 | 94.4 | 95.2 | 92.1. | 88.9 | 92.2 | 0.003 |
| (94.1–94.7) | (94.9–95.5) | (91.2–92.8) | (86.3–91.1) | (90.3–93.7) | ||
| 40–64 | 94.9 | 95.3 | 93.8 | 88.9 | 92.3 | 0.012 |
| (94.4–95.4) | (94.7–95.8) | (91.6–95.4) | (84.2–92.3) | (88.3–94.9) | ||
| 65+ | 82.8 | 84.1 | 79.0 | 46.9 | 65.6 | 0.008 |
| (77.4–87.1) | (78.2–88.5) | (57.5–90.5) | (12.7–75.7) | (41.9–81.6) | ||
| Marital status | ||||||
| Single | 92.1 | 92.9 | 90.3 | 86.2 | 90.0 | < 0.001 |
| (91.7–92.5) | (92.4–93.4) | (89.2–91.4) | (83.0–88.8) | (87.4–92.0) | ||
| Married | 96.7 | 97.0 | 95.6 | 92.4 | 93.5 | < 0.001 |
| (96.4–97.0) | (96.7–97.4) | (94.5–96.5) | (88.7–94.9) | (90.9–95.4) | ||
| Separated/D/W | 90.3 | 90.8 | 865 | 87.8 | 91.8 | 0.221 |
| (88.8–91.6) | (89.2–92.2) | (81.3–90.3) | (76.8–93.8) | (80.3–96.7) | ||
| Stage at diagnosis | ||||||
| Localized | 98.7 | 98.9 | 98.2 | 97.1 | 97.8 | 0.002 |
| (98.5–98.9) | (98.6–99.1) | (97.5–98.7) | (94.9–98.3) | (96.2–98.7) | ||
| Regional | 94.9 | 95.3 | 94.5 | 87.7 | 91.0 | 0.009 |
| (94.3–95.4) | (94.6–95.9) | (92.8–95.8) | (82.0–91.7) | (86.3–94.1) | ||
| Distant | 69.6 | 71.0 | 67.5 | 58.4 | 62.8 | < 0.001 |
| (68.2–70.9) | (69.4–72.5) | (64.3–70.4) | (50.6–65.5) | (55.2–69.5) | ||
| Location | ||||||
| Undescended | 93.4 | 93.7 | 92.0 | 90.7 | 95.5 | < 0.001 |
| testis | (91.1–95.2) | (90.7–95.8) | (85.2–95.8) | (75.9–96.6) | (83.8–98.8) | |
| Descended | 95.6 | 96.8 | 92.6 | 91.1 | 93.1 | < 0.001 |
| testis | (95.2–96.0) | (96.3–97.2) | (91.4–93.6) | (86.5–94.2) | (89.8–95.3) | |
| Testis (NOS) | 93.8 | 94.3 | 92.1 | 87.8 | 90.7 | < 0.001 |
| (93.5–94.1) | (94.0–94.7) | (91.0–93.1) | (84.9–90.1) | (88.5–92.5) | ||
| Histologic subtype | ||||||
| Seminomas | 97.9 | 98.1 | 97.3 | 96.4 | 96.6 | < 0.001 |
| (97.6–98.2) | (97.8–98.4) | (96.5–98.0) | (93.9–97.9) | (94.7–97.8) | ||
| Teratomas | 93.0 | 93.8 | 90.8 | 84.7 | 90.7 | < 0.001 |
| (92.5–93.5) | (93.2–94.4) | (89.3–92.1) | (78.8–89.0) | (86.7–93.5) | ||
| ECs | 91.2 | 91.4 | 90.7 | 79.2 | 89.4 | < 0.001 |
| (90.4–92.0) | (90.5–92.3) | (88.2–92.8) | (69.0–86.4) | (83.3–93.4) | ||
| Non-seminomas | 83.8 | 87.1 | 74.5 | 76.1 | 75.9 | < 0.001 |
| (81.2–86.0) | (84.1–89.5) | (67.8–80.0) | (58.5–87.0) | (58.4–86.9) | ||
| Treatment | ||||||
| Surgery | 97.0 | 97.2 | 96.6 | 91.6 | 96.7 | 0.259 |
| (96.5–97.4) | (96.6–97.6) | (94.6–97.9) | (86.2–95.0) | (90.2–98.4) | ||
| Chemotherapy | 57.2 | 56.2 | 68.7 | 38.2 | 58.7 | < 0.001 |
| (51.8–62.3) | (49.8–62.0) | (53.1–80.0) | (17.4–58.9) | (80.8–89.5) | ||
| Radiation | 83.9 | 86.9 | 66.7 | 50.3 | 97.3 | < 0.001 |
| (72.5–90.9) | (75.0–93.3) | (5.4–94.5) | (0.6–981.2) | (93.5–98.9) | ||
| RS | 99.1 | 99.1 | 99.5 | 98.3 | 98.0 | 0.007 |
| (98.7–99.4) | (98.6–99.4) | (97.5–99.9) | (93.3–99.6) | (95.0–99.2) | ||
| CS | 89.5 | 89.9 | 89.6 | 84.4 | 83.8 | 0.003 |
| (88.7–90.3) | (89.0–90.7) | (86.6–92.0) | (77.7–89.3) | (78.4–88.0) | ||
| CR | 36.0 | 44.9 | 18.8 | 40.2 | 40.7 | < 0.001 |
| (22.0–50.1) | (26.8–61.4) | (1.1–53.7) | (5.2–75.5) | (19.8–60.8) | ||
| CRS | 63.4 | 65.6 | 59.5 | 65.1 | 43.9 | 0.946 |
| (58.4–67.9) | (60.0–70.6) | (43.2–72.6) | (37.8–82.8) | (19.9–65.7) | ||
Cancers were diagnosed in the period from 1973 to 2010 and followed up to 12/31/2015 using data in the SEER 9 database. Data are estimated rates (95% confidence intervals). ECs: embryonal carcinomas.
NHW non-Hispanic whites, HW Hispanic whites, API Asians and Pacific Islanders, ECs embryonal carcinomas, RS radiotherapy plus surgery, CS chemotherapy plus surgery, CR chemotherapy plus radiotherapy, CRS chemotherapy plus radiotherapy plus surgery